Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study.
Cachexia index
Gastric cancer
Prognosis
Unresectable
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
21
04
2023
accepted:
13
06
2023
medline:
1
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
aheadofprint
Résumé
To investigate the prognostic utility of the cachexia index (CXI) in unresectable advanced gastric cancer (UAGC). The relationship between CXI and the outcomes was evaluated in 102 patients with UAGC who had received first-line palliative 5-fluorouracil-based chemotherapy between January 2012 and December 2021. The median survival time (MST) from first-line chemotherapy initiation was 16.2 months, and the cohort included 60 and 42 patients with high and low CXIs, respectively, based on the optimal CXI cutoff. The rates of patients with a performance status score of 0, recurrence, third-line chemotherapy, and all grade 3-4 side effects, including febrile neutropenia (FN), were significantly higher in the CXI Patients with UAGC and a low CXI had poorer prognoses and more frequent grade 3-4 side effects, including FN, than those with a high CXI. Patients with UAGC and a low CXI should be carefully managed to control for side effects to receive subsequent treatment.
Identifiants
pubmed: 37526733
doi: 10.1007/s00595-023-02721-w
pii: 10.1007/s00595-023-02721-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
Références
Lei X, Wang Y, Shan F, Li S, Jia Y, Miao R, et al. Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials. World J Surg Oncol. 2022;20(1):405.
doi: 10.1186/s12957-022-02818-5
pubmed: 36566193
pmcid: 9789553
Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer. 2019;22(3):598–606.
doi: 10.1007/s10120-018-0884-0
pubmed: 30284080
Chu YN, Yu YN, Jing X, Mao T, Chen YQ, Zhou XB, et al. Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer. World J Gastroenterol. 2019;25(35):5344–55.
doi: 10.3748/wjg.v25.i35.5344
pubmed: 31558878
pmcid: 6761234
Fujiya K, Tokunaga M, Nishiwaki N, Furukawa K, Omori H, Kaji S, et al. Feasibility of laparoscopic distal gastrectomy for stage i gastric cancer in patients outside of clinical trials. J Gastrointest Surg. 2018;22(10):1665–71.
doi: 10.1007/s11605-018-3842-6
pubmed: 29916107
Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14.
doi: 10.3748/wjg.v22.i8.2403
pubmed: 26937129
pmcid: 4768187
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.
doi: 10.1016/S0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Murakami Y, Saito H, Shimizu S, Kono Y, Shishido Y, Miyatani K, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with unresectable gastric cancer. Anticancer Res. 2019;39(5):2583–9.
doi: 10.21873/anticanres.13381
pubmed: 31092456
Namikawa T, Shimizu S, Yokota K, Tanioka N, Munekage M, Uemura S, et al. Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer. Langenbecks Arch Surg. 2022;407(2):609–21.
doi: 10.1007/s00423-021-02356-w
pubmed: 34652563
Tanioka H, Okawaki M, Yano S, Yoshimitsu T, Tokuda K, Nyuya A, et al. Neutrophil-to-lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer. Oncol Lett. 2023;25(3):98.
doi: 10.3892/ol.2023.13684
pubmed: 36817039
pmcid: 9931998
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.
doi: 10.1038/nrdp.2017.105
pubmed: 29345251
da Rocha IMG, Marcadenti A, de Medeiros GOC, Bezerra RA, Rego JFM, Gonzalez MC, et al. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle. 2019;10(2):445–54.
doi: 10.1002/jcsm.12391
pubmed: 30924270
pmcid: 6463470
Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol. 2015;9:87–93.
doi: 10.4137/CMO.S30891
pubmed: 26604850
pmcid: 4640427
Go SI, Park MJ, Park S, Kang MH, Kim HG, Kang JH, et al. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma. J Cachexia Sarcopenia Muscle. 2021;12(6):2211–9.
doi: 10.1002/jcsm.12837
pubmed: 34676685
pmcid: 8718032
Kang Z, Cheng L, Li K, Shuai Y, Xue K, Zhong Y, et al. Correlation between L3 skeletal muscle index and prognosis of patients with stage IV gastric cancer. J Gastrointest Oncol. 2021;12(5):2073–81.
doi: 10.21037/jgo-21-556
pubmed: 34790375
pmcid: 8576239
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.
doi: 10.1186/1475-2891-9-69
pubmed: 21176210
pmcid: 3019132
Hamura R, Haruki K, Shirai Y, Tanji Y, Taniai T, Okui N, et al. Preoperative cachexia index can predict the prognosis of extrahepatic biliary tract cancer after resection. Surg Oncol. 2022;44:101825.
doi: 10.1016/j.suronc.2022.101825
pubmed: 35947886
Akaoka M, Haruki K, Taniai T, Yanagaki M, Igarashi Y, Furukawa K, et al. Clinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection. Surg Oncol. 2022;45:101881.
doi: 10.1016/j.suronc.2022.101881
pubmed: 36371905
(2021) Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24(1):1–21
(2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20(1):1–19
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9)
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Gong C, Wan Q, Zhao R, Zuo X, Chen Y, Li T (2022) Cachexia index as a prognostic indicator in patients with gastric cancer: a retrospective study. Cancers (Basel) 14(18)
Goh MJ, Kang W, Jeong WK, Sinn DH, Gwak GY, Paik YH, et al. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Sci Rep. 2022;12(1):7647.
doi: 10.1038/s41598-022-11736-1
pubmed: 35538112
pmcid: 9090914
Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen R, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–74.
doi: 10.1002/jcsm.12468
pubmed: 31389674
pmcid: 6903439
Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, et al. Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis. Front Nutr. 2022;9:978110.
doi: 10.3389/fnut.2022.978110
pubmed: 36590214
pmcid: 9794869
de Pablos-Rodríguez P, Del Pino-Sedeño T, Infante-Ventura D, de Armas-Castellano A, Ramírez Backhaus M, Ferrer JFL et al (2022) Prognostic impact of sarcopenia in patients with advanced prostate carcinoma: a systematic review. J Clin Med 12(1)
Matsunaga T, Saito H, Miyauchi W, Shishido Y, Miyatani K, Morimoto M, et al. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil. BMC Cancer. 2021;21(1):1219.
doi: 10.1186/s12885-021-08953-8
pubmed: 34774016
pmcid: 8590780
Sohda M, Sakai M, Yamaguchi A, Watanabe T, Nakazawa N, Ubukata Y, et al. Pre-treatment CRP and albumin determines prognosis for unresectable advanced oesophageal cancer. In Vivo. 2022;36(4):1930–6.
doi: 10.21873/invivo.12914
pubmed: 35738616
pmcid: 9301391
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.
pubmed: 28850174
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234–47.
doi: 10.1016/S1470-2045(21)00692-6
pubmed: 35030335
Iizumi S, Takashima A, Sakamaki K, Morita S, Boku N. Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2018;81(6):981–9.
doi: 10.1007/s00280-018-3569-9
pubmed: 29600386
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.
doi: 10.1016/S0140-6736(17)31827-5
pubmed: 28993052
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–48.
doi: 10.1016/S1470-2045(18)30739-3
pubmed: 30355453
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–8.
doi: 10.1093/annonc/mdu472
pubmed: 25316259
Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98(11):2402–9.
doi: 10.1002/cncr.11827
pubmed: 14635075
Aagaard T, Roen A, Reekie J, Daugaard G, Brown PN, Specht L, et al. Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI Cancer Spectr. 2018;2(4):pky053.
doi: 10.1093/jncics/pky053
pubmed: 31360873
pmcid: 6649794
Nara K, Yamamoto T, Sato Y, Yagi K, Kawasaki K, Toriumi T, et al. Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. Support Care Cancer. 2023;31(2):150.
doi: 10.1007/s00520-023-07609-6
pubmed: 36737558
pmcid: 9898323
Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321–36.
doi: 10.2217/pgs.11.72
pubmed: 21919607
Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015;125:217–43.
doi: 10.1016/bs.acr.2014.10.007
pubmed: 25640272
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640–5.
doi: 10.1038/clpt.2013.172
pubmed: 23988873
pmcid: 3831181
Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol. 2002;54(2):131–9.
doi: 10.1046/j.1365-2125.2002.01598.x
pubmed: 12207632
pmcid: 1874401